<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02612519</url>
  </required_header>
  <id_info>
    <org_study_id>Agua-Trial</org_study_id>
    <nct_id>NCT02612519</nct_id>
  </id_info>
  <brief_title>Alfapump System Versus Transjugular Intrahepatic Portosystemic Shunt and Paracentesis in the Treatment of Ascites</brief_title>
  <official_title>Alfapump System Versus Transjugular Intrahepatic Portosystemic Shunt and Paracentesis in the Treatment of Ascites. A Multicentre Randomised Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Leipzig</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentre, open, randomised, and controlled trial conducted in patients diagnosed with&#xD;
      recurrent/refractory ascites who meet inclusion/exclusion criteria. The efficacy of the&#xD;
      Alfapump, TIPS and paracentesis with regard to the treatment of ascites will be compared. All&#xD;
      patients will receive medical care for cirrhosis and ascites according to the institution's&#xD;
      standards of care. Standard of care may include, but is not limited to the administration of&#xD;
      diuretics, paracentesis and consideration for orthotopic liver transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include patients with decompensated liver cirrhosis and recurrent or&#xD;
      refractory, with regular requirements for large volume paracentesis (see subject inclusion&#xD;
      criteria). With respect to TIPS-contraindications patients will be assigned to two&#xD;
      substudies. If no TIPS-contraindications exists (sub-study 1) patients will be randomized to&#xD;
      Alfapump or TIPS. The presence of at least one TIPS-contraindication (sub-study 2) is leading&#xD;
      to a randomization to Alfapump or standard of care. All patients will receive medical care&#xD;
      for cirrhosis and ascites according to the institution's standards medical care. Standard of&#xD;
      care may include, but is not limited to, administration of diuretics, paracentesis and&#xD;
      consideration for orthotopic liver transplantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low recruitement rate&#xD;
  </why_stopped>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">April 30, 2019</completion_date>
  <primary_completion_date type="Actual">April 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome is the (average) number of paracenteses per quarter during time without device abandonment, transplant, or death documented on a time horizon of 4 quarters (i.e.1 year).</measure>
    <time_frame>Starts with randomisation and ends after 12 months or when a device abandonment, transplant, or death occurs before.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of paracenteses per quarter during time without device abandonment, transplant, or death documented on a time horizon of 24 months.</measure>
    <time_frame>Starts with randomisation and ends after 24 months or when a device abandonment, transplant, or death occurs before.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of paracenteses per quarter during time without transplant or death documented on a time horizon of 24 months.</measure>
    <time_frame>Starts with randomisation and ends after 24 months or when transplant or death occurs before.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant-free survival</measure>
    <time_frame>From randomisation to 24 months or to death, censoring patients alive at the date of last information or at the date of orthotopic liver transplantation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of device abandonment</measure>
    <time_frame>Starts with randomisation and ends after 24 months or when transplant or death occurs before.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of ascites removed</measure>
    <time_frame>Starting four weeks after study inclusion and ending after 24 months or when transplant or death occurs before.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Quality of Life (EQ-5D Questionnaire)</measure>
    <time_frame>Starts with randomisation and ends after 24 months or when transplant or death occurs before.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and duration of hospital stays</measure>
    <time_frame>Starts with randomisation and ends after 24 months or when transplant or death occurs before.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutrition status, assessed by time course of upper arm girth [cm]</measure>
    <time_frame>Starts with randomisation and ends after 24 months or when transplant or death occurs before.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin substitution, assessed as total amount per quarter [g].</measure>
    <time_frame>Starts with randomisation and ends after 24 months or when transplant or death occurs before.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of first occurrence of hepatic encephalopathy Stage 2 or higher</measure>
    <time_frame>Starts with randomisation and ends after 12 months months or when a device abandonment, transplant, or death occurs before.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Alfapump - Substudy 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alfapump implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIPS - Substudy 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TIPS implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alfapump - Substudy 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alfapump implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard - Substudy 2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Alfapump</intervention_name>
    <description>Implantation of Alfapump</description>
    <arm_group_label>Alfapump - Substudy 1</arm_group_label>
    <arm_group_label>Alfapump - Substudy 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TIPS</intervention_name>
    <description>Implantation of TIPS</description>
    <arm_group_label>TIPS - Substudy 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Cirrhosis of the liver&#xD;
&#xD;
          2. Recurrent or refractory ascites&#xD;
&#xD;
          3. Age ≥ 18 years (at informed consent)&#xD;
&#xD;
          4. Written informed consent&#xD;
&#xD;
          5. Expected ability to operate the Alfapump device&#xD;
&#xD;
          6. Alcohol abstinence ≥ 3 months at date of inclusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. General contraindications indicating an advanced stage of liver cirrhosis:&#xD;
&#xD;
               -  Bilirubin &gt; 5 mg/dl and/or&#xD;
&#xD;
               -  INR &gt; 1.5 (without oral anticoagulant such as Vitamin K antagonists or new oral&#xD;
                  anticoagulants (NOAKs), which inhibit the determination of INR. Therefore&#xD;
                  patients must be switched to alternative anticoagulants such as heparin or low&#xD;
                  molecular heparin or fondaparinux that do not interfere with INR measurements)&#xD;
                  and/or&#xD;
&#xD;
               -  Serum-Sodium &lt; 130 mmol/l and/or&#xD;
&#xD;
               -  ECOG &gt; 2 (Performance status)&#xD;
&#xD;
          2. Gastrointestinal haemorrhage during the last 7 days before inclusion&#xD;
&#xD;
          3. Renal failure defined as serum creatinine higher than or equal to 1,5 mg/dl at time of&#xD;
             inclusion&#xD;
&#xD;
          4. Clinical evidence of recurring bacterial peritonitis, defined as 2 or more episodes&#xD;
             over the last 6 months or a single episode within the last 2 weeks before inclusion.&#xD;
&#xD;
          5. Clinical evidence of recurring urinary infections, defined as 2 or more episodes over&#xD;
             the last 6 months or a single episode within the last 2 weeks before inclusion.&#xD;
&#xD;
          6. Clinical evidence of loculated ascites.&#xD;
&#xD;
          7. Residual urinary volume exceeding 100 ml if obstructive uropathy is known or suspected&#xD;
&#xD;
          8. Known bladder anomaly which might contraindicate implantation of the device.&#xD;
&#xD;
          9. Known or suspected hepatic or extra hepatic malignancy, unless adequately treated and&#xD;
             in complete remission for ≥ 3 years&#xD;
&#xD;
         10. Known active chronic hepatitis C (unless adequately treated, i.e no Virus-RNA&#xD;
             detectable after cessation of antiviral treatment)&#xD;
&#xD;
         11. Acute peritonitis&#xD;
&#xD;
         12. Pregnant or nursing women. (A serum pregnancy test is required for fertile women&#xD;
             within two years of their last menstruation.)&#xD;
&#xD;
         13. Fertile women (within two years of their last menstruation) without appropriate&#xD;
             contraceptive measures (implantation, injections, oral contraceptives, intrauterine&#xD;
             devices, partner with vasectomy) while participating in the trial&#xD;
&#xD;
         14. Suspected lack of compliance&#xD;
&#xD;
         15. Patients enrolled in another interventional clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Berg, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uniklinik Leipzig Sektion Hepatologie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizische Klinik III</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik 1 - Gastroenterologie</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>November 11, 2015</study_first_submitted>
  <study_first_submitted_qc>November 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2015</study_first_posted>
  <last_update_submitted>July 29, 2019</last_update_submitted>
  <last_update_submitted_qc>July 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leipzig</investigator_affiliation>
    <investigator_full_name>Cornelius Engelmann</investigator_full_name>
    <investigator_title>Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

